Dopamine

Overview

Dopamine is a rapid-acting injectable catecholamine inotrope used in dogs and cats for the management of hypotension associated with decreased cardiac output or systemic vasodilation. It is administered as a continuous intravenous infusion (CRI) in critical care settings where close cardiovascular monitoring is available.

It is commonly used in patients with shock after adequate fluid resuscitation, as well as in anesthetized patients experiencing hypotension. Dopamine is not recommended for improving renal perfusion or urine output in dogs and cats, as evidence does not support a beneficial effect on glomerular filtration rate.

Mechanism of Action (MOA): Dopamine acts directly and indirectly on adrenergic receptors by stimulating beta-1 receptors at moderate doses, leading to increased cardiac contractility, heart rate, and cardiac output. At higher doses, alpha-1 receptor stimulation predominates, resulting in increased systemic vascular resistance and blood pressure. Dopamine also has dopaminergic effects but these are not clinically reliable for renal support in dogs and cats.

Indications

Dopamine is used in dogs and cats as a rapid-acting inotropic and vasopressor agent for the management of hypotension associated with impaired cardiac function or systemic vasodilation. It is typically reserved for use in critical care settings after adequate fluid resuscitation.

• Shock and hypotension: Used to treat hypotension associated with low cardiac output or peripheral vasodilation once adequate circulating volume has been restored.
• Adjunct in congestive heart failure: Provides positive inotropic support in acute cases to improve cardiac output and tissue perfusion.
• Anesthesia-associated hypotension: Used to maintain blood pressure in patients under general anesthesia when hypotension occurs.
• Critical care support: Administered as a continuous infusion in intensive care settings where continuous monitoring of cardiovascular parameters is available.

Dosage (Reference)

Dog

In dogs, dopamine is administered as a continuous intravenous infusion (CRI) in critical care settings to manage severe hypotension. Dose should be titrated based on clinical response with continuous cardiovascular monitoring.

Cat

In cats, dopamine is used similarly as in dogs for management of hypotension, with careful titration and close monitoring due to potential variability in response.

Warnings & Precautions

Dopamine is a potent cardiovascular agent that must be used only in controlled critical care settings with continuous monitoring. Careful patient selection, dose titration, and monitoring are essential to minimize adverse effects and complications.

• Contraindications: Do not use in patients with pheochromocytoma, ventricular fibrillation, or uncorrected tachyarrhythmias.
• Not a substitute for fluid therapy: Dopamine should only be used after adequate fluid, electrolyte, or blood volume replacement has been achieved.
• Cardiac monitoring required: Continuous monitoring of heart rate, rhythm, and blood pressure is essential due to risk of arrhythmias and rapid hemodynamic changes.
• Arrhythmias and ischemia: Use cautiously in patients with ischemic heart disease or pre-existing arrhythmias; reduce dose or discontinue if arrhythmias develop.
• Peripheral vasoconstriction: Excessive vasoconstriction may impair perfusion to extremities or vital organs; monitor for signs of reduced circulation.
• MAO inhibitors: Dose should be significantly reduced in patients receiving monoamine oxidase inhibitors due to prolonged and exaggerated effects.
• Renal effects: Not recommended for increasing glomerular filtration rate or urine output, as clinical benefit has not been demonstrated in dogs and cats.
• Extravasation risk: Leakage from the IV site may cause local tissue irritation; monitor infusion site closely.
• Critical care use only: Should only be administered in settings where intensive monitoring (e.g., ECG, blood pressure) is available.

Drug Interactions

Clinically relevant interactions with dopamine are primarily related to its adrenergic activity and metabolism. Careful dose adjustment and monitoring are required when used with the following medications.

• Monoamine oxidase inhibitors (MAOIs): Markedly potentiate and prolong the effects of dopamine; substantial dose reduction is required to avoid excessive cardiovascular stimulation.
• Other sympathomimetic agents: Concurrent use may result in additive effects, increasing the risk of tachycardia, hypertension, and arrhythmias.
• Inhalant anesthetics (e.g., isoflurane): May increase myocardial sensitivity to catecholamines, raising the risk of arrhythmias during dopamine infusion.

Side Effects & Overdose

Side Effects

Adverse effects of dopamine are primarily related to its dose-dependent cardiovascular and adrenergic activity and are more likely to occur with higher infusion rates or inadequate monitoring.

• Gastrointestinal signs: Nausea and vomiting may occur, particularly at higher doses.
• Cardiac arrhythmias: Ectopic beats and tachycardia are common; ventricular arrhythmias may occur.
• Blood pressure instability: Both hypotension and hypertension may develop depending on dose and patient response.
• Respiratory effects: Dyspnea may occur in some patients.
• Peripheral vasoconstriction: May reduce perfusion to extremities or vital organs at higher doses.

Overdose

Overdose or excessive infusion rates can result in severe cardiovascular complications due to excessive adrenergic stimulation.

• Severe hypertension: Due to excessive peripheral vasoconstriction.
• Serious arrhythmias: Tachyarrhythmias or ventricular arrhythmias that may be life-threatening.
• Reduced tissue perfusion: Severe vasoconstriction may compromise perfusion to vital organs and extremities.
• Management: Reduce or discontinue infusion; stepwise dose reduction is recommended to avoid rebound hypotension, with supportive care and close monitoring.

Key Notes

Practical clinical considerations for the safe and effective use of dopamine in dogs and cats:

• Rapid onset and short duration: Effects begin within minutes of starting infusion and dissipate quickly after stopping, allowing precise control over hemodynamic support.
• CRI-dependent effect: Clinical effects are directly dependent on continuous infusion rate, requiring careful titration to achieve desired cardiovascular response.
• Dose-dependent receptor activity: Lower to moderate doses primarily enhance cardiac contractility, while higher doses increase vascular resistance and blood pressure.
• No oral efficacy: Not effective when given orally due to rapid metabolism and lack of systemic absorption.
• Short half-life: Plasma half-life is approximately 2 minutes, necessitating continuous administration to maintain effect.
• Does not cross blood-brain barrier: Central nervous system effects are minimal due to limited penetration.
• Metabolism: Rapidly metabolized by MAO and COMT in liver, kidney, and plasma to inactive metabolites.